Paul Hallenbeck | Founder And Chief Executive Officer
Seneca Therapeutics

Dr Hallenbeck is the founder & CEO of Seneca Therapeutics. He is a multiple award winning, serial entrepreneur, with 27 years in the biotechnology industry with expertise in all phases of cancer immunotherapeutics R&D. As the sole founder of Neotropix he raised $30M in VC, then successfully led SVV (NTX-001) through IND approval, and completed several phase I/II clinical trials, establishing an excellent safety record and compelling evidence of efficacy.